PharmaCyte Biotech (PMCB) 10-Q 18 Mar 24 2024 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Jan. 31, 2024	Mar. 15, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jan. 31, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--04-30
Entity File Number	001-40699
Entity Registrant Name	PHARMACYTE BIOTECH, INC.
Entity Central Index Key	0001157075
Entity Tax Identification Number	62-1772151
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	3960 Howard Hughes Parkway
Entity Address, Address Line Two	Suite 500
Entity Address, City or Town	Las Vegas
Entity Address, State or Province	NV
Entity Address, Postal Zip Code	89169
City Area Code	(917)
Local Phone Number	595-2850
Title of 12(b) Security	Common Stock, Par Value $0.0001 Per Share
Trading Symbol	PMCB
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,464,824

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Current assets:
Cash and cash equivalents	$ 61,210,328	$ 68,039,936
Prepaid expenses and other current assets	297,762	107,681
Total current assets	61,508,090	68,147,617
Other assets:
Intangibles	3,549,427	3,549,427
Investment in SG Austria	1,572,193	1,572,193
Convertible note receivable	2,012,000	0
Warrant asset	2,710,000	0
Other assets	7,688	7,688
Total other assets	9,851,308	5,129,308
Total Assets	71,359,398	73,276,925
Current liabilities:
Accounts payable	484,198	128,281
Accrued expenses	774,439	458,300
Accrued Series B convertible preferred stock redemptions and dividends	6,280,102	0
Total current liabilities	7,538,739	586,581
Other liabilities:
Warrant liability	11,494,000	0
Derivative liability	3,433,000	0
Total other liabilities	14,927,000	0
Total Liabilities	22,465,739	586,581
Commitments and Contingencies (Notes 7 and 9)
Stockholders' equity:
Preferred stock value	0	0
Common stock, authorized: 200,000,000 shares, $0.0001 par value; 21,672,078 shares issued and 8,521,159 shares outstanding as of January 31, 2024 and 21,602,078 shares issued and 16,793,980 shares outstanding as of April 30, 2023	2,167	2,160
Additional paid-in capital	189,221,416	202,230,583
Accumulated deficit	(116,971,711)	(115,958,773)
Treasury stock, at cost, 13,150,919 and 4,808,098 shares as of January 31, 2024 and April 30, 2023, respectively	(40,853,840)	(13,560,623)
Accumulated other comprehensive loss	(23,073)	(23,003)
Total stockholders' equity	31,374,959	72,690,344
Total Liabilities, Convertible Preferred Stock and Stockholders' Equity	71,359,398	73,276,925
Series B Preferred Stock [Member]
Convertible Preferred Stock:
Convertible preferred stock	17,518,700	0
Series A Preferred Stock [Member]
Stockholders' equity:
Preferred stock value	$ 0	$ 0

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) (Parenthetical) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares authorized	200,000,000	200,000,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares issued	21,672,078	21,602,078
Common stock, shares outstanding	8,521,159	16,793,980
Treasury stock, common shares	13,150,919	4,808,098
Series B Preferred Stock [Member]
Temporary equity, shares authorized	35,000	35,000
Temporary equity, par value	$ 0.0001	$ 0.0001
Temporary equity, face value	$ 1,000	$ 1,000
Temporary equity, shares issued	23,397	0
Temporary equity, shares outstanding	23,397	0
Shares excluded for redemption	8,083	0
Temporary Equity, Liquidation Preference	$ 23,769,945	$ 0
Series A Preferred Stock [Member]
Preferred stock, shares authorized	1	1
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Revenue	$ 0	$ 0	$ 0	$ 0
Operating expenses:
Research and development costs	126,732	45,393	313,248	382,662
Compensation expense	620,777	251,556	1,089,934	979,694
Director fees	638,762	795,969	995,715	951,031
Legal and professional	230,772	103,180	1,075,073	2,454,227
General and administrative	251,903	356,885	1,879,822	784,597
Total operating expenses	1,868,946	1,552,983	5,353,792	5,552,211
Loss from operations	(1,868,946)	(1,552,983)	(5,353,792)	(5,552,211)
Other income (expenses):
Interest income	881,662	635,889	2,651,721	1,214,562
Change in fair value of warrant liability	10,000	0	2,633,000	0
Change in fair value of derivative liability	636,000	0	(663,000)	0
Change in fair value of convertible note receivable	138,000	0	138,000	0
Change in fair value of warrant asset	(416,000)	0	(416,000)	0
Other income (expense), net	(253)	152,958	(2,867)	147,994
Total other income, net	1,249,409	788,847	4,340,854	1,362,556
Net loss	(619,537)	(764,136)	(1,012,938)	(4,189,655)
Preferred stock dividends	(781,507)	0	(1,688,242)	0
Preferred stock accretion	(4,219,069)	0	(11,995,681)	0
Net loss attributable to common stockholders	$ (5,620,113)	$ (764,136)	$ (14,696,861)	$ (4,189,655)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) (Parenthetical) - $ / shares	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Basic loss per share attributable to common stockholders	$ (0.65)	$ (0.04)	$ (1.47)	$ (0.21)
Diluted loss per share attributable to common stockholders	$ (0.65)	$ (0.04)	$ (1.47)	$ (0.21)
Weighted average shares outstanding basic	8,606,957	18,995,442	9,991,326	20,051,617
Weighted average shares outstanding diluted	8,606,957	18,995,442	9,991,326	20,051,617

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Income Statement [Abstract]
Net loss	$ (619,537)	$ (764,136)	$ (1,012,938)	$ (4,189,655)
Other comprehensive loss:
Foreign currency translation	1,070	(2,554)	(70)	(1,970)
Other comprehensive income (loss)	1,070	(2,554)	(70)	(1,970)
Comprehensive loss	$ (618,467)	$ (766,690)	$ (1,013,008)	$ (4,191,625)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock, Common [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Apr. 30, 2022	$ 0	$ 2,072	$ 201,582,107	$ 0	$ (111,648,656)	$ (15,757)	$ 89,919,766
Beginning balance, shares at Apr. 30, 2022	0	20,721,047		0
Stock issued for compensation			2,750				2,750
Stock issued for services			2,278				2,278
Stock issued for services, shares		1,002
Stock-based compensation options			4,595				4,595
Stock issued for warrant exercise		$ 88	792				880
Stock issued for warrant exercise, shares		880,000
Foreign currency translation adjustment						1,304	1,304
Net loss					(1,545,012)		(1,545,012)
Repurchase of common stock				$ (2,090,847)			(2,090,847)
Repurchase of common stock, shares				(851,981)
Ending balance, value at Jul. 31, 2022	$ 0	$ 2,160	201,592,522	$ (2,090,847)	(113,193,668)	(14,453)	86,295,714
Ending balance, shares at Jul. 31, 2022	0	21,602,049		(851,981)
Beginning balance, value at Apr. 30, 2022	$ 0	$ 2,072	201,582,107	$ 0	(111,648,656)	(15,757)	89,919,766
Beginning balance, shares at Apr. 30, 2022	0	20,721,047		0
Net loss							(4,189,655)
Ending balance, value at Jan. 31, 2023	$ 0	$ 2,160	202,230,583	$ (9,254,005)	(115,838,311)	(17,727)	77,122,700
Ending balance, shares at Jan. 31, 2023	0	21,602,078		(3,393,060)
Beginning balance, value at Jul. 31, 2022	$ 0	$ 2,160	201,592,522	$ (2,090,847)	(113,193,668)	(14,453)	86,295,714
Beginning balance, shares at Jul. 31, 2022	0	21,602,049		(851,981)
Stock issued for compensation			3,917				3,917
Stock options granted			4,212				4,212
Reverse stock split adjustment
Reverse stock split adjustment, shares		29
Foreign currency translation adjustment						(720)	(720)
Net loss					(1,880,507)		(1,880,507)
Repurchase of common stock				$ (3,385,044)			(3,385,044)
Repurchase of common stock, shares				(1,223,153)
Ending balance, value at Oct. 31, 2022	$ 0	$ 2,160	201,600,651	$ (5,475,891)	(115,074,175)	(15,173)	81,037,572
Ending balance, shares at Oct. 31, 2022	0	21,602,078		(2,075,134)
Stock issued for compensation			667				667
Stock options granted			629,265				629,265
Reverse stock split adjustment
Foreign currency translation adjustment						(2,554)	(2,554)
Net loss					(764,136)		(764,136)
Repurchase of common stock				$ (3,778,114)			(3,778,114)
Repurchase of common stock, shares				(1,317,926)
Ending balance, value at Jan. 31, 2023	$ 0	$ 2,160	202,230,583	$ (9,254,005)	(115,838,311)	(17,727)	77,122,700
Ending balance, shares at Jan. 31, 2023	0	21,602,078		(3,393,060)
Beginning balance, value at Apr. 30, 2023	$ 0	$ 2,160	202,230,583	$ (13,560,623)	(115,958,773)	(23,003)	72,690,344
Beginning balance, shares at Apr. 30, 2023	0	21,602,078		(4,808,098)
Stock issued for warrant exercise		$ 7	63				70
Stock issued for warrant exercise, shares		70,000
Series B preferred stock dividends			(319,849)				(319,849)
Preferred stock accretion	3,272,033		(3,272,033)				(3,272,033)
Foreign currency translation adjustment						451	451
Net loss					(3,183,297)		(3,183,297)
Repurchase of common stock				$ (26,721,897)			(26,721,897)
Repurchase of common stock, shares				(8,085,879)
Issuance of Series B Preferred Stock, net of discounts and issuance costs of $18,246,925	$ 16,753,075
Issuance of Series B Preferred Stock, net of discounts and issuance costs, shares	35,000
Ending balance, value at Jul. 31, 2023	$ 20,025,108	$ 2,167	198,638,764	$ (40,282,520)	(119,142,070)	(22,552)	39,193,789
Ending balance, shares at Jul. 31, 2023	35,000	21,672,078		(12,893,977)
Beginning balance, value at Apr. 30, 2023	$ 0	$ 2,160	202,230,583	$ (13,560,623)	(115,958,773)	(23,003)	72,690,344
Beginning balance, shares at Apr. 30, 2023	0	21,602,078		(4,808,098)
Net loss							$ (1,012,938)
Repurchase of common stock, shares		(8,342,821)					(256,942)
Ending balance, value at Jan. 31, 2024	$ 17,518,700	$ 2,167	189,221,416	$ (40,853,840)	(116,971,711)	(23,073)	$ 31,374,959
Ending balance, shares at Jan. 31, 2024	23,397	21,672,078		(13,150,919)
Beginning balance, value at Jul. 31, 2023	$ 20,025,108	$ 2,167	198,638,764	$ (40,282,520)	(119,142,070)	(22,552)	39,193,789
Beginning balance, shares at Jul. 31, 2023	35,000	21,672,078		(12,893,977)
Series B preferred stock subject to redemption	$ (3,188,536)
Series B preferred stock subject to redemption, shares	(3,520)
Series B preferred stock dividends			(586,886)				(586,886)
Preferred stock accretion	4,461,097		(4,461,097)				(4,461,097)
Foreign currency translation adjustment						(1,591)	(1,591)
Net loss					2,789,896		2,789,896
Repurchase of common stock				$ (166,603)			(166,603)
Repurchase of common stock, shares				(78,109)
Ending balance, value at Oct. 31, 2023	$ 21,297,669	$ 2,167	193,590,781	$ (40,449,123)	(116,352,174)	(24,143)	36,767,508
Ending balance, shares at Oct. 31, 2023	31,480	21,672,078		(12,972,086)
Stock-based compensation options			674,693				674,693
Series B preferred stock subject to redemption	$ (8,041,520)
Series B preferred stock subject to redemption, shares	(8,083)
Series B preferred stock dividends			(781,507)				(781,507)
Preferred stock accretion	4,262,551		(4,262,551)				(4,262,551)
Foreign currency translation adjustment						1,070	1,070
Net loss					(619,537)		(619,537)
Repurchase of common stock				$ (404,717)			$ (404,717)
Repurchase of common stock, shares				(178,833)			(178,833)
Ending balance, value at Jan. 31, 2024	$ 17,518,700	$ 2,167	$ 189,221,416	$ (40,853,840)	$ (116,971,711)	$ (23,073)	$ 31,374,959
Ending balance, shares at Jan. 31, 2024	23,397	21,672,078		(13,150,919)

CONDENSED CONSOLIDATED STATEM_5

CONDENSED CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (UNAUDITED) (Parenthetical)	3 Months Ended
	Jul. 31, 2023 USD ($)
Preferred Stock [Member]
Net of discounts and issuance costs	$ 18,246,925

CONDENSED CONSOLIDATED STATEM_6

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Cash flows from operating activities:
Net loss	$ (1,012,938)	$ (4,189,655)
Adjustments to reconcile net loss to net cash used in operating activities:
Other non-cash expense	0	165,868
Stock issued for services	0	2,278
Stock issued for compensation	0	7,334
Stock-based compensation	674,693	638,072
Change in fair value of warrant liability	(2,633,000)	0
Change in fair value of derivative liability	663,000	0
Change in fair value of convertible note receivable	(138,000)	0
Change in fair value of warrant asset	416,000	0
Change in assets and liabilities:
Increase in prepaid expenses and other current assets	(190,081)	(86,836)
Increase in accounts payable	355,918	74,706
Increase (decrease) in accrued expenses	45,909	(117,110)
Net cash used in operating activities	(1,818,499)	(3,505,343)
Cash flows from investing activities:
Investment - note receivable and warrants	(5,000,000)	0
Net cash used in investing activities	(5,000,000)	0
Cash flows from financing activities:
Repurchase of common stock	(27,022,987)	(9,254,005)
Proceeds from issuance of preferred stock, net of transaction costs	33,650,075	0
Redemption of preferred stock	(6,638,197)	0
Proceeds from warrant exercise	70	880
Net cash used in financing activities	(11,039)	(9,253,125)
Effect of currency rate exchange on cash and cash equivalents	(70)	(1,970)
Net decrease in cash and cash equivalents	(6,829,608)	(12,760,438)
Cash and cash equivalents at beginning of the periods	68,039,936	85,400,656
Cash and cash equivalents at end of the periods	61,210,328	72,640,218
Supplemental disclosure of cash flows information:
Cash paid during the periods for income taxes	1,600	0
Supplemental schedule of non-cash investing and financing activities:
Non-cash derivative liability at initial fair value	2,770,000	0
Non-cash warrant liability at initial fair value	14,127,000	0
Reclassification of Series B Convertible Preferred Stock and dividends to current liability	12,918,299	0
Accretion of discounts to redemption value of Series B Preferred Stock	11,995,681	0
Excise tax accrued on repurchase of common stock	$ 270,230	$ 0

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($)	3 Months Ended						9 Months Ended
	Jan. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Jan. 31, 2024	Jan. 31, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss) Attributable to Parent	$ (619,537)	$ 2,789,896	$ (3,183,297)	$ (764,136)	$ (1,880,507)	$ (1,545,012)	$ (1,012,938)	$ (4,189,655)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Jan. 31, 2024
Trading Arrangements, by Individual [Table]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

NATURE OF BUSINESS

NATURE OF BUSINESS	9 Months Ended
	Jan. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
NATURE OF BUSINESS	NOTE 1 – NATURE OF BUSINESS PharmaCyte Biotech, Inc. (“Company”) is a biotechnology company focused on developing cellular therapies for cancer, diabetes and malignant ascites based upon a proprietary cellulose-based live cell encapsulation technology known as “Cell-in-a-Box ® ® The Company is a Nevada corporation incorporated in 1996. In 2013, the Company restructured its operations to focus on biotechnology. The Company acquired licenses from SG Austria Pte. Ltd., a Singapore corporation (“SG Austria”) to treat cancer and Austrianova Singapore Pte. Ltd., a Singapore corporation (“Austrianova Singapore”) to treat diabetes using the Cell-in-the-Box technology. The restructuring resulted in the Company focusing all its efforts upon the development of a novel, effective and safe way to treat cancer and diabetes. In January 2015, the Company changed its name from Nuvilex, Inc. to PharmaCyte Biotech, Inc. to reflect the nature of its current business. In October 2021, the Company moved its headquarters from Laguna Hills, California to Las Vegas, Nevada. On September 1, 2020, the Company submitted an Investigational New Drug Application (“IND”) to the United States Food and Drug Administration (“FDA”) for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the IND on clinical hold. On October 30, 2020, the FDA sent a letter to the Company setting forth the reasons for the clinical hold and specific guidance on what the Company must do to have the clinical hold lifted. To lift the clinical hold, the FDA informed the Company that it needs to conduct several additional preclinical studies. The FDA also requested additional information regarding several topics, including DNA sequencing data, manufacturing information and product release specifications. The Company has been in the process of conducting these studies and gathering additional information to submit to the FDA. See “Investigational New Drug Application and Clinical Hold” below. On August 15, 2022, the Company entered into a Cooperation Agreement (“Cooperation Agreement”) with Iroquois Master Fund Ltd. and its affiliates, pursuant to which the Company elected a reconstituted Board of Directors (“Board”). The Board has formed a Business Review Committee to evaluate, investigate and review the Company’s business, affairs, strategy, management and operations and in its sole discretion to make recommendations to the Company’s management and Board with respect thereto. The Business Review Committee is also reviewing many of the risks relative to the Company’s business. In addition, the Board is reviewing the Company’s development programs and its relationship with SG Austria, including that all licensed patents have expired, that know-how relating to the Company’s Cell-in-a-Box® technology solely resides with SG Austria, and that the incentives of SG Austria and its management may not be currently aligned with those of the Company. The Board has curtailed spending on the Company’s programs, including pre-clinical and clinical activities, until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented. The Business Review Committee’s recommendations will include potentially seeking a new framework for the Company’s relationship with SG Austria and its subsidiaries. In the event the Company is unsuccessful in seeking an acceptable new framework, the Company will reevaluate whether it should continue those programs which are dependent on SG Austria, including its development programs for LAPC, diabetes and malignant ascites. The issues involving SG Austria have delayed the Company’s timeline for addressing the FDA clinical hold for its planned clinical trial in LAPC and could result in other delays or termination of the development activities. In addition, the curtailment of spending on the Company’s programs pending the review by the Business Review Committee and the Board may cause additional delays. The Cell-in-a-Box ® The Company has been developing therapies for pancreatic and other solid cancerous tumors by using genetically engineered live human cells that it believes are capable of converting a cancer prodrug into its cancer-killing form. The Company encapsulates those cells using the Cell-in-a-Box ® The Company has also been developing a way to delay the production and accumulation of malignant ascites that results from many types of abdominal cancerous tumors. The Company’s therapy for malignant ascites involves using the same encapsulated cells it employs for pancreatic cancer but placing the encapsulated cells in the peritoneal cavity of a patient and administering ifosfamide intravenously. In addition to the two cancer programs discussed above, the Company has been working on ways to exploit the benefits of the Cell-in-a-Box ® Cannabis ® Finally, the Company has been developing a potential therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes. The Company’s product candidate for the treatment of diabetes consists of encapsulated genetically modified insulin-producing cells. The encapsulation will be done using the Cell-in-a-Box ® Until the review by the Business Review Committee and the Board is complete and the Board has determined the actions and plans to be implemented, spending on the Company’s programs has been curtailed. Investigational New Drug Application and Clinical Hold On September 1, 2020, the Company submitted an IND to the FDA for a planned clinical trial in LAPC. On October 1, 2020, the Company received notice from the FDA that it had placed the Company’s IND on clinical hold. On October 30, 2020, the FDA sent the Company a letter setting forth the reasons for the clinical hold and providing specific guidance on what the Company must do to have the clinical hold lifted. In order to address the clinical hold, the FDA requested that the Company: · Provide additional sequencing data and genetic stability studies; · Conduct a stability study on ‌the Company’s final formulated product candidate as well as the cells from the Company’s Master Cell Bank; · Evaluate the compatibility of the delivery devices (the prefilled syringe and the microcatheter used to implant the CypCaps ™ · Provide additional detailed description of the manufacturing process of ‌the Company’s product candidate for pancreatic cancer; · Provide additional product release specifications for the Company’s encapsulated cells; · Demonstrate comparability between the 1 st nd · Conduct a biocompatibility assessment using the Company’s capsules material; · Address specified insufficiencies in the Chemistry, Manufacturing and Controls information in the cross-referenced Drug Master File; · Conduct an additional nonclinical study in a large animal (such as a pig) to assess the safety, activity, and distribution of the product candidate for pancreatic cancer; and · Revise the Investigators Brochure to include any additional preclinical studies conducted in response to the clinical hold and remove any statements not supported by the data the Company generated. The FDA also requested that the Company address the following issues as an amendment to the Company’s IND: · Provide a Certificate of Analysis for pc3/2B1 plasmid that includes tests for assessing purity, safety, and potency; · Perform qualification studies for the drug substance filling step to ensure that the Company’s product candidate for pancreatic cancer remains sterile and stable during the filling process; · Submit an updated batch analysis for the Company’s product candidate for the specific lot that will be used for manufacturing all future product candidates; · Provide additional details for the methodology for the Resorufin (CYP2B1) potency and the PrestoBlue cell metabolic assays; · Provide a few examples of common microcatheters that fit the specifications in ‌the Company’s Angiography Procedure Manual; · Clarify the language in ‌our Pharmacy Manual regarding proper use of the syringe fill with the Company’s product candidate for pancreatic cancer; and · Provide a discussion with data for trial of the potential for cellular and humoral immune reactivity against the heterologous rat CYP2B1 protein and potential for induction of autoimmune-mediated toxicities in ‌our study population. The Company assembled a scientific and regulatory team of experts to address the FDA requests. That team has been working diligently to complete the items requested by the FDA. The Company is conducting studies of the technology. The Company has completed the pilot study of two pigs and is evaluating the preliminary data before commencing the larger study of 90 pigs. Nasdaq Listing The Company’s common stock began trading on Nasdaq on August 10, 2021, under the symbol “PMCB.” Prior to that, the Company’s common stock was quoted on the OTCQB Market under the symbol “PMCB.” Increase in Authorized Shares On September 6, 2023, pursuant to stockholder approval received at a special meeting of stockholders, the Company filed with the Secretary of State of the State of Nevada a Certificate of Change to its Articles of Incorporation, as amended, to increase the number of authorized shares of common stock from 133,333,334 to 200,000,000 10,000,000

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation and Basis of Presentation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech, Inc. and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the Rules and Regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated. The Company’s 14.3 325 Investments Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in accordance with U.S. GAAP. U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s condensed consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations. Cash and Cash Equivalents Cash and cash equivalents include cash in banks and short-term liquid investments purchased with maturities of three months or less. Intangible Assets The Financial Accounting Standards Board (“FASB”) standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year. The Company’s intangible assets are in process R&D obtained through the acquisition of licensing agreements related to the Cell-in-a-Box ® 1,549,427 2,000,000 3,549,427 These intangible assets have an indefinite life; therefore, they are not amortizable. The Company concluded that there was no Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No Convertible Note Receivable As permitted under Financial Accounting Standards Board ("FASB”) ASC 825, Financial Instruments ("ASC 825”), the Company elects to account for its convertible note receivable, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value, including interest, are recorded as a component of non-operating income (loss) in the condensed consolidated statements of operations. As a result of electing the fair value option, direct costs and fees related to the convertible note receivable were expensed as incurred. The Company estimates the fair value of the convertible note receivable using the income approach, which uses as inputs the fair value of debtor’s common stock and estimates for the equity volatility and volume volatility of debtor’s common stock, the time to expiration of the convertible note, the discount rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of debtor’s common stock and historical volatility of debtor’s common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using the S&P Global default rate for companies with a similar credit rating to debtor’s. Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the Condensed Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of valuation hierarchy are defined as follows: · Level 1. Observable inputs such as quoted prices in active markets · Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and · Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. These unobservable inputs are significant to the fair value measurement. Income Taxes Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. A valuation allowance is provided for deferred income tax assets when, in management’s judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the condensed consolidated statements of operations. The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authorities or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates. Consideration of Inflation Reduction Act Excise Tax On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly-traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The Company repurchased 8,342,821 27,293,217 178,833 404,717 270,230 Research and Development Research and development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, which are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established. R&D costs for the three months ended January 31, 2024 and 2023 were $ 126,732 45,393 313,248 382,662 Stock-Based Compensation The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option’s expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future. Concentration of Credit Risk The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at financial institutions located throughout the United States. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation up to $ 250,000 16,480,000 1,100,000 Foreign Currency Translation The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters

INVESTMENT IN DEBT AND EQUITY S

INVESTMENT IN DEBT AND EQUITY SECURITIES	9 Months Ended
	Jan. 31, 2024
Investments, Debt and Equity Securities [Abstract]
INVESTMENT IN DEBT AND EQUITY SECURITIES	NOTE 3 – INVESTMENT IN DEBT AND EQUITY SECURITIES On November 14, 2023, the Company entered into a Securities Purchase Agreement (the “Femasys Purchase Agreement”) with Femasys Inc. (“Femasys”), pursuant to which it agreed to purchase from Femasys for a sum of $5,000,000 (i) senior unsecured convertible notes (the “Femasys Notes”) in an aggregate principal amount of $ 5,000,000 1.18 4,237,288 1.18 4,237,288 1.475 The Femasys Notes accrue interest at 6.0% per annum, payable annually, and mature two years after the date of issuance. The Femasys Warrants expire five years from the date of issuance. Pursuant to the terms of the Femasys Purchase Agreement, the Company’s interim Chief Executive Officer was appointed to the Femasys board of directors. The convertible note receivable is not traded in active markets and the fair value was determined using a Monte Carlo simulation. The convertible note receivable is accounted for as available-for-sale debt securities based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset. The Company elected the fair value option for the Femasys Notes, therefore, holding gains and losses are included within change in fair value of the notes in the consolidated statement of operations. The Femasys Warrants are accounted for as an equity security and are valued using a Monte Carlo simulation based on “Level 3” inputs, which consist of unobservable inputs and reflect management’s estimates of assumptions that market participants would use in pricing the asset, recorded at fair value with subsequent changes included within change in fair value of the warrants in the consolidated statement of operations. The Company recognized the Femasys Note and Femasys Warrants based on their respective fair values on the issuance date of $ 1,874,000 3,126,000 138,000 416,000 Below is a summary of activity for the Note and Warrants as of January 31, 2024: Schedule of notes and warrants receivable Balance of Notes as of May 1, 2023 $ – Issued 1,874,000 Change in fair value 138,000 Balance of Notes as of January 31, 2024 $ 2,012,000 Balance of Warrants as of May 1, 2023 $ – Issued 3,126,000 Change in fair value (416,000 ) Balance of Warrants as of January 31, 2024 $ 2,710,000

ACCRUED EXPENSES

ACCRUED EXPENSES	9 Months Ended
	Jan. 31, 2024
Payables and Accruals [Abstract]
ACCRUED EXPENSES	NOTE 4 – ACCRUED EXPENSES Accrued expenses at January 31, 2024 and April 30, 2023, are summarized below: Schedule of accrued expenses January 31, 2024 April 30, 2023 Payroll related costs $ 158,803 $ 112,894 R&D costs, including related parties 287,310 287,310 Other, including excise tax on stock repurchases 328,326 58,096 Total $ 774,439 $ 458,300

COMMON STOCK TRANSACTIONS

COMMON STOCK TRANSACTIONS	9 Months Ended
	Jan. 31, 2024
Equity [Abstract]
COMMON STOCK TRANSACTIONS	NOTE 5 – COMMON STOCK TRANSACTIONS A summary of the Company’s compensatory stock activity and related weighted average grant date fair value information for the three and nine months ended January 31, 2024 and 2023 is as follows: In January 2022, the Company awarded 4,400 0 7,333 zero During the nine months ended January 31, 2023, three non-employee members of the Board were issued 1,002 0 0 2,278 zero All shares were issued without registration under the Securities Act of 1933 as amended (“Securities Act”) in reliance upon the exemption afforded by Section 4(a)(2) of the Securities Act. There were no

STOCK OPTIONS AND WARRANTS

STOCK OPTIONS AND WARRANTS	9 Months Ended
	Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]
STOCK OPTIONS AND WARRANTS	NOTE 6 – STOCK OPTIONS AND WARRANTS 2022 Equity Incentive Plan Effective December 28, 2022, the Company implemented the 2022 Equity Incentive Plan (“2022 Equity Plan”) as approved by the Company’s stockholders. The 2022 Equity Plan is administered by the Compensation Committee of the Board and has 2,750,000 Stock Options As of January 31, 2024, the Company had 779,794 During the nine months ended January 31, 2024 and 2023, the Company granted 499,992 251,002 The fair value of the Employee Options at the date of grant was estimated using the Black-Scholes-Merton option-pricing model, based on the following weighted average assumptions: Schedule of assumptions for options Nine Months Ended January 31, 2024 2023 Risk-free interest rate 4.42 3.30 Expected volatility 115 133 Expected lives (years) 5.1 3.5 Expected dividend yield 0.00 0.00 For stock option grants issued during the nine months ended January 31, 2024 and 2023, the Company used a calculated volatility for each grant based on the Company’s historical stock values. The Company lacks adequate information about the exercise behavior now and has determined the expected term assumption under the simplified method provided for under ASC 718, which averages the contractual term of the Company’s stock options of ten years with the average vesting term of six months. The dividend yield assumption of zero is based upon the fact the Company has never paid cash dividends and presently has no intention of paying cash dividends. The risk-free interest rate used for each grant is equal to the U.S. Treasury rates in effect at the time of the grant for instruments with a similar expected life. A summary of the Company’s stock option activity and related information for the nine months ended January 31, 2024, are shown below: Schedule of stock option activity Options Number of Options Weighted Average Grant Date Fair Value per Share Outstanding, April 30, 2023 281,269 $ 6.94 Issued 499,992 2.18 Expired (1,467 ) 89.10 Outstanding, January 31, 2024 779,794 $ 3.73 Exercisable, January 31, 2024 652,294 $ 4.04 Vested and expected to vest 779,794 $ 3.73 There were 127,500 The Company recorded $ 674,693 629,264 674,693 638,072 234,692 The following table summarizes the outstanding stock options by exercise price at January 31, 2024: Schedule of options by exercise price Exercise Price Number of Weighted Weighted Number of Weighted Average $ 74.25 6,000 0.13 $ 74.25 6,000 $ 74.25 $ 57.00 800 0.64 $ 57.00 800 $ 57.00 $ 60.60 667 0.25 $ 60.60 667 $ 60.60 $ 55.50 333 0.41 $ 55.50 333 $ 55.50 $ 51.00 333 0.69 $ 51.00 333 $ 51.00 $ 61.20 6,000 0.92 $ 61.20 6,000 $ 61.20 $ 36.00 667 1.25 $ 36.00 667 $ 36.00 $ 37.05 333 1.41 $ 37.05 333 $ 37.05 $ 15.75 333 1.69 $ 15.75 333 $ 15.75 $ 10.05 6,000 1.92 $ 10.05 6,000 $ 10.05 $ 26.55 667 2.25 $ 26.55 667 $ 26.55 $ 16.20 333 2.41 $ 16.20 333 $ 16.20 $ 3.19 334 2.69 $ 3.19 334 $ 3.19 $ 2.50 6,000 2.92 $ 2.50 6,000 $ 2.50 $ 2.29 668 3.25 $ 2.29 668 $ 2.29 $ 2.24 334 3.41 $ 2.24 334 $ 2.24 $ 2.97 250,000 8.79 $ 2.97 250,000 $ 2.97 $ 2.18 499,992 9.81 $ 2.18 372,492 $ 2.18 Total 779,794 3.73 $ 4.04 652,294 $ 4.04 The aggregate intrinsic value of outstanding options as of January 31, 2024 was $ 3,725 Warrants Pursuant to the Private Placement (as defined below), the Company issued investors Warrants (as defined below) to purchase 8,750,000 4.00 The Warrants were determined to be within the scope of ASC 480-10 as they are puttable to the Company at Holders’ election upon the occurrence of a Fundamental Transaction (as defined in the agreements). As such, the Company recorded the Warrants as a liability at fair value with subsequent changes in fair value recognized in earnings. The Company utilized the Black-Scholes-Merton Model to calculate the value of the Warrants issued during the nine months ended January 31, 2024. The fair value of the Warrants of approximately $ 14,127,000 Transaction costs incurred attributable to the issuance of the Warrants of approximately $ 0.9 During the nine months ended January 31, 2024, the Company recorded a gain of approximately $ 2,633,000 11,494,000 A summary of the Company’s warrant activity and related information for the nine months ended January 31, 2024, are shown below: Schedule of warrant activity Warrants Weighted Per Share Outstanding, April 30, 2023 9,890,847 $ 4.99 Issued 8,750,000 4.00 Exercised (70,000 ) – Expired – – Outstanding, January 31, 2024 18,570,847 – Exercisable, January 31, 2024 18,570,847 $ 4.54 The following table summarizes additional information concerning warrants outstanding and exercisable at January 31, 2024: Schedule of warrants outstanding and exercisable Exercise Prices Number of Weighted Weighted $ 4.25 1,506,141 2.53 $ 5.3125 264,706 2.52 $ 5.00 7,000,000 2.56 $ 6.25 1,050,000 2.55 $ 4.00 8,750,000 4.28 18,570,847 3.37 $ 4.54

LEGAL PROCEEDINGS

LEGAL PROCEEDINGS	9 Months Ended
	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
LEGAL PROCEEDINGS	NOTE 7 – LEGAL PROCEEDINGS From time to time, the Company is subject to legal proceedings and claims, either asserted or unasserted, that arise in the ordinary course of business. While the outcome of pending claims cannot be predicted with certainty, the Company does not believe that the outcome of any pending claims will have a material adverse effect on our financial condition or operating results. On December 4, 2023, H.C. Wainwright & Co., LLC (“Wainwright”) filed a complaint against the Company in the Supreme Court of the State of New York, County of New York, asserting a single cause of action for breach of contract and alleging that the Company breached an April 2021 engagement agreement with Wainwright by failing to pay a purported “tail fee” allegedly due in connection with a private placement transaction that closed in 2023. Wainwright seeks damages of not less than $1,950,000, warrants to purchase an aggregate of 656,250 shares of our common stock at an exercise price of $5.00 per share, and attorney’s fees. On February 28, 2024, the Company responded to the complaint with an answer and affirmative defenses. The Company intends to vigorously defend against Wainwright’s complaint and does not believe that any potential loss is reasonably estimable at this time. To our knowledge there are no other legal proceedings pending to which any property of the Company is subject.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Jan. 31, 2024
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	NOTE 8 – RELATED PARTY TRANSACTIONS The Company had the following related party transactions during the three and nine months ended January 31, 2024 and 2023, respectively. The Company owns 14.3 0 0 0 64,000 In April 2014, the Company entered the Vin-de-Bona Consulting Agreement pursuant to which it agreed to provide professional consulting services to the Company. Vin-de-Bona is owned by Prof. Günzburg and Dr. Salmons, both of whom are involved in numerous aspects of the Company’s scientific endeavors relating to cancer and diabetes (Prof. Günzburg is the Chairman of Austrianova, and Dr. Salmons is the Chief Executive Officer and President of Austrianova). The term of the agreement is for 12 months and is automatically renewable for successive 12-month terms. After the initial term, either party can terminate the agreement by giving the other party 30 days’ written notice before the effective date of termination. To date, the agreement has been automatically renewed annually. The amounts incurred for the three months ended January 31, 2024 and 2023, were approximately $ 2,600 2,400 5,300 47,500 The Company’s Interim Chief Executive Officer was appointed to the Femasys board of directors, see Note 3.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Jan. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	NOTE 9 – COMMITMENTS AND CONTINGENCIES The Company acquires assets still in development and enters R&D arrangements with third parties that often require milestone and royalty payments to the third-party contingent upon the occurrence of certain future events linked to the success of the asset in development. Milestone payments may be required, contingent upon the successful achievement of an important point in the development lifecycle of the pharmaceutical product (e.g., approval of the product for marketing by a regulatory agency). If required by the license agreements, the Company may have to make royalty payments based upon a percentage of the sales of the pharmaceutical products if regulatory approval for marketing is obtained. Office Lease In January 2022, the Company entered into a six-month lease of the Las Vegas, Nevada office space, commencing on May 1, 2022, which expired on October 31, 2022. In July 2022, the Company entered into an additional six-month lease of the Las Vegas, Nevada office space, commencing on November 1, 2022, which expired on April 30, 2023. In January 2023, the Company entered into a month-to-month agreement of the Las Vegas office space, commencing on May 1, 2023. Additionally, the Company rents storage space pursuant to a month-to-month agreement in Laguna Hills, California. Rent expenses for the office for the three and nine months ended January 31, 2024 were $ 6,825 22,424 5,789 17,041 With the month-to-month office rental agreements there are no aggregate future minimum lease payments required to be made. Compensation Agreements On January 1, 2022, the Company entered into an amended and restated executive compensation agreement with Carlos A. Trujillo, the Company’s Chief Financial Officer. The compensation agreement for Mr. Trujillo has a term of three years, with automatic renewals unless the Company or Mr. Trujillo provides written notice of termination at least ninety days prior to the end of the current term. As of January 31, 2024, the Company had five directors. Each non-employee director was entitled to receive $12,500 in cash for each calendar quarter of service on the Board. Effective November 20, 2023, each non-employee director is entitled to receive $15,000 each quarter of service on the Board, plus an additional $2,500 quarterly for each non-employee director who serves as chair of the Board’s audit committee, compensation committee or nominating and corporate governance committee. On August 15, 2022, the Company and the Board: (i) accepted the previously tendered irrevocable resignation of each of Dr. Matthias Löhr, Dr. Raymond C.F. Tong, Thomas Liquard, Dr. Gerald W. Crabtree, and Carlos A. Trujillo, as members of the Board, and (ii) appointed Jonathan L. Schechter, Joshua N. Silverman, Daniel Allen, Daniel S. Farb, and Jack E. Stover as independent members of the Board, effective immediately, each with a term expiring at the Company’s 2022 annual meeting of shareholders or until such person’s earlier death, resignation, disqualification or removal. On November 1, 2022, Jack E. Stover notified the Company of his decision to resign from the Board effective immediately. On November 14, 2022, in accordance with the recommendation of the Company’s Nominating Committee, Robert Weinstein was appointed to serve as a director of the Board and the Chairperson of the Audit Committee, with a term expiring at the Company’s annual meeting of shareholders or until death, resignation, disqualification or removal. On November 14, 2022, the Board approved the employment of Mr. Joshua Silverman as the Interim Chief Executive Officer, Interim President and Interim Chairman of the Board on a month-to-month basis. Upon Mr. Silverman accepting employment he was no longer an independent director. On December 28, 2022, the Company held its annual meeting of stockholders. The stockholders voted to elect the following directors to serve one-year terms expiring at the annual meeting of stockholders to be held during the year ended April 30, 2024: Joshua N. Silverman, Jonathan L. Schechter, Michael M. Abecassis, Robert Weinstein and Wayne R. Walker. Service Agreements The Company has entered into several service agreements with independent and related parties pursuant to which services will be provided over a specified period-of-time related to the IND which the FDA has placed on clinical hold. The services include regulatory affairs strategy, advice and follow up work on the IND and services related to having the clinical hold lifted. The total cost is estimated to be approximately $332,000, of which the related party (SG Austria and its subsidiaries) portion will be approximately $157,000. These amounts take into account some of the cost associated with the work and preclinical studies required to lift the clinical hold.

INCOME TAXES

INCOME TAXES	9 Months Ended
	Jan. 31, 2024
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 10 – INCOME TAXES At January 31, 2024, the Company had federal and state net operating loss carryforwards of approximately $ 58,018,000 49,924,000 39,336,000 20,958,000 9,117,000 Current tax laws limit the amount of loss available to be offset against future taxable income when a substantial change in ownership occurs. Therefore, the amount available to offset future taxable income may be limited. Based on the assessment of all available evidence including, but not limited to, the Company’s limited operating history in its core business and lack of profitability, uncertainties of the commercial viability of its technology, the impact of government regulations and healthcare reform initiatives and other risks normally associated with biotechnology companies, the Company has concluded that is more likely than not that these operating loss carryforwards will not be realized. Accordingly, 100% of the deferred tax valuation allowance has been recorded against these assets. The Company’s policy is to recognize any interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of the nine months ended January 31, 2024 and 2023, the Company had accrued no See Note 9 of Notes to the Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended April 30, 2023, for additional information regarding income taxes.

EARNINGS PER SHARE

EARNINGS PER SHARE	9 Months Ended
	Jan. 31, 2024
Earnings Per Share [Abstract]
EARNINGS PER SHARE	NOTE 11 – EARNINGS PER SHARE Basic earnings (loss) per share is computed by dividing earnings (loss) available to common stockholders by the weighted average number of shares outstanding during the period. Diluted earnings per share is computed by dividing net income by the weighted average number of shares and potentially dilutive shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would be outstanding if the potentially dilutive securities had been issued. Potential shares of common stock outstanding principally include preferred stock, stock options and warrants. During the three and nine months ended January 31, 2024 and 2023, the Company incurred losses attributable to common stockholders. Accordingly, the effect of any common stock equivalent would be anti-dilutive during those periods and are not included in the calculation of diluted weighted average number of shares outstanding. The table below sets forth the basic loss per share calculations: Schedule of earnings (loss) per share Three Months Ended January 31, 2024 2023 Net loss attributable to common stockholders $ (5,620,113 ) $ (764,136 ) Basic and diluted weighted average number of shares outstanding 8,606,957 18,995,442 Basic and diluted loss per share $ (0.65 ) $ (0.04 ) Nine Months Ended January 31, 2024 2023 Net loss attributable to common stockholders $ (14,696,861 ) $ (4,189,655 ) Basic and diluted weighted average number of shares outstanding 9,991,326 20,051,617 Basic and diluted loss per share $ (1.47 ) $ (0.21 ) The table below sets forth these potentially dilutive securities: Schedule of potentially dilutive securities Nine Months Ended January 31, 2024 2023 Excluded options 779,794 281,936 Excluded warrants 18,570,847 9,890,847 Series B convertible preferred stock 5,929,053 – Total preferred stock, options and warrants 25,279,694 10,172,783

PREFERRED STOCK

PREFERRED STOCK	9 Months Ended
	Jan. 31, 2024
Equity [Abstract]
PREFERRED STOCK	NOTE 12 – PREFERRED STOCK The Company has authorized 10,000,000 0.0001 35,000 23,397 zero 8,083 zero On May 10, 2023, the Company entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (the “Investors”), pursuant to which it agreed to sell to the Investors (i) an aggregate of 35,000 shares of the Company’s newly-designated Series B convertible preferred stock with a stated value of $1,000 per share, initially convertible into up to 8,750,000 shares of the Company’s common stock, par value $0.0001 per share at a conversion price of $4.00 per share (the “Preferred Shares”), and (ii) warrants to acquire up to an aggregate of 8,750,000 shares of common stock (the “Warrants”) (collectively, the “Private Placement”). The terms of the Preferred Shares are as set forth in a Certificate of Designations (the “Certificate of Designations”), which was filed with the Secretary of the State of Nevada on May 10, 2023. The Preferred Shares are convertible into common stock (the “Conversion Shares”) at the election of the holder at any time at an initial conversion price of $4.00 (the “Conversion Price”). The Conversion Price is subject to customary adjustments for stock dividends, stock splits, reclassifications and the like, and subject to price-based adjustment in the event of any issuances of common stock, or securities convertible, exercisable or exchangeable for common stock, at a price below the then-applicable Conversion Price (subject to certain exceptions). The Company is required to settle the Preferred Shares in equal monthly installments, commencing on November 9, 2023. The amortization payments due upon such redemption are payable, at the Company’s election, in cash, or subject to certain limitations, in shares of common stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 20% discount to the average of the three lowest closing prices of the Company’s common stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the lower of $0.556 and 20% of the Minimum Price (as defined in Rule 5635 of the Rule of the Nasdaq Stock Market) on the date of receipt of Nasdaq Stockholder Approval (as defined below); provided that if the amount set forth in clause B is the lowest effective price, the Company will be required to pay the amortization payment in cash. The Company may require holders to convert their Preferred Shares into Conversion Shares if the closing price of the common stock exceeds $6.00 per share for 20 consecutive trading days and the daily trading volume of the common stock exceeds 1,000,000 shares per day during the same period and certain equity conditions described in the Certificate of Designations are satisfied. The holders of the Preferred Shares are entitled to dividends of 4% per annum, compounded monthly, which are payable in cash or shares of common stock at the Company’s option, in accordance with the terms of the Certificate of Designations. Upon the occurrence and during the continuance of a Triggering Event (as defined in the Certificate of Designations), the Preferred Shares will accrue dividends at the rate of 15% per annum. The holders of Preferred Shares have no voting rights on account of the Preferred Shares, other than with respect to certain matters affecting the rights of the Preferred Shares. Notwithstanding the foregoing, the Company’s ability to settle conversions and make amortization payments using shares of common stock is subject to certain limitations set forth in the Certificate of Designations, including a limit on the number of shares that may be issued until the time, if any, that the Company’s stockholders have approved the issuance of more than 19.9% of the Company’s outstanding shares of common stock in accordance with Nasdaq listing standards (the “Nasdaq Stockholder Approval”). The Company received Nasdaq Stockholder Approval at its special meeting of stockholders held on August 31, 2023. Further, the Certificate of Designations contains a certain beneficial ownership limitation after giving effect to the issuance of shares of common stock issuable upon conversion of, or as part of any amortization payment under, the Certificate of Designations or Warrants. The Certificate of Designations includes certain Triggering Events (as defined in the Certificate of Designations), including, among other things, the failure to file and maintain an effective registration statement covering the sale of the holder’s securities registrable pursuant to a registration rights agreement entered into by the Company and the Investors simultaneously with the Purchase Agreement and the Company’s failure to pay any amounts due to the holders of the Preferred Shares when due. In connection with a Triggering Event, each holder of Preferred Shares will be able to require the Company to redeem in cash any or all of the holder’s Preferred Shares at a premium set forth in the Certificate of Designations. The Preferred Shares were determined to be more akin to a debt-like host than an equity-like host. The Company identified the following embedded features that are not clearly and closely related to the debt host instrument: 1) an installment redemption upon an Equity Conditions Failure (as defined in the Certificate of Designation), and 2) variable share-settled installment conversion. These features were bundled together, assigned probabilities of being affected and measured at fair value. Subsequent changes in the fair value of these features are recognized in the Condensed Consolidated Statements of Operations. The Company estimated the $2.8 million fair value of the bifurcated embedded derivative at issuance using a Monte Carlo simulation model, with the following inputs: the fair value of the Company’s common stock of $2.74 on the issuance date, estimated equity volatility of 55.0%, estimated traded volume volatility of 355.0%, the time to maturity of 1.50 years, a discounted market interest rate of 15.9%, a risk free rate of 4.3%, dividend rate of 4.0%, a penalty dividend rate of 15.0%, and probability of default of 27.0%. The fair value of the bifurcated derivative liability was estimated utilizing the with and without method which uses the probability weighted difference between the scenarios with the derivative and the plain vanilla maturity scenario without a derivative. The discount to the fair value is included as a reduction to the carrying value of the Preferred Shares. During the nine months ended January 31, 2024, the Company recorded a total discount of approximately $ 18.2 2.8 1.3 14.1 During the three and nine months ended January 31, 2024, the Company recorded a gain of approximately $ 0.7 3.4 During the three and nine months ended January 31, 2024, the Company made all installment payments in cash pursuant to installment redemptions. The first three installment redemptions were paid in cash in the amounts of $6,638,196, which includes $ 5,770,833 491,616 8,041,520 11,995,681 499,417 As of January 31, 2024, the Company has reclassified a portion of the Preferred Shares to an accrued liability for the fourth and fifth installment redemptions owed to investors in cash of $6,280,102 which includes $5,833,333 of the stated value of the Preferred Shares, $103,039 of dividends payable, and $343,730 of additional 6% cash premium pursuant to the terms of the Series B Preferred stock. The Company provided notice to the investors of their intent to redeem the first five installments in cash prior to January 31, 2024. The Company has one share of preferred stock designated as “Series A Preferred Stock” as of January 31, 2024 and April 30, 2023, there were no shares of Series A Preferred Stock issued and outstanding. The description of the Series A Preferred Stock below is qualified in its entirety by reference to the Company’s Articles of Incorporation, as amended. The Series A Preferred Stock has the following features: · There is one share of preferred stock designated as Series A Preferred Stock; · The Series A Preferred Stock has a number of votes at any time equal to the number of votes then held by all other shareholders of the Company having a right to vote on any matter plus one. The Certificate of Designations that designated the terms of the Series A Preferred Stock cannot be amended without the consent of the holder of the Series A Preferred Stock; · The Company may redeem the Series A Preferred Stock at any time for a redemption price of $1.00 paid to the holder of the share of Series A Preferred Stock; and · The Series A Preferred Stock has no rights of transfer, conversion, dividends, preferences upon liquidation or participation in any distributions to shareholders.

TREASURY STOCK

TREASURY STOCK	9 Months Ended
	Jan. 31, 2024
Equity [Abstract]
TREASURY STOCK	NOTE 13 – TREASURY STOCK In May 2022, the Board authorized a share repurchase program to acquire its outstanding common stock for up to $ 10 178,833 256,942 5,065,040 14,131,942 5,868,058 Tender Offer On May 11, 2023, the Company commenced a tender offer, in accordance with Rule 13e-4 promulgated under the Securities Exchange Act of 1934, as amended, to purchase up to 7,750,000 shares of its common stock, par value $0.0001 per share, at a price of $3.25 per share. The tender offer expired one minute after 11:59 p.m. on June 9, 2023, and following such expiration the Company accepted for purchase a total of 8,085,879 26,721,897 As of January 31, 2024, the total number of shares held in Treasury Stock is 13,150,919 40,853,840

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	NOTE 14 – FAIR VALUE MEASUREMENTS Fair value measurements discussed herein are based upon certain market assumptions and pertinent information available to management as of and during the nine months ended January 31, 2024. The carrying amounts of cash equivalents, other current assets, accounts payable and accrued expenses approximate their fair values at January 31, 2024 due to their short-term nature. The fair value of the bifurcated embedded derivative related to the convertible preferred stock was estimated using a Monte Carlo simulation model, which uses as inputs the fair value of the Company’s common stock and guideline companies estimates for the equity volatility and traded volume volatility of our common stock, the time maturity of the convertible preferred stock, the risk-free interest rate for a period of time that approximates the time to maturity, dividend rate, a penalty dividend rate and the probability of default. The fair value of the warrant liability was estimated using the Black Scholes Merton Model which uses as inputs the following weighted average assumptions, as noted above: dividend yield, expected terms in years, equity volatility and risk-free rate. Fair Value on a Recurring Basis The Company follows the guidance in ASC 820 for its financial assets and liabilities that are re-measured and reported and reported at fair at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. The estimated fair value of the warrant liability and bifurcated embedded derivative represent Level 3 measurements. The following table presents information about the Company’s liabilities that are measured at fair value on a recurring basis at January 31, 2024, and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value: Schedule of liabilities measured at fair value on a recurring basis Description Level January 31, 2024 April 30, 2023 Liabilities: Warrant liability (Note 5) 3 $ 11,494,000 $ – Bifurcated embedded derivative (Note 11) 3 $ 3,433,000 $ – The following table sets forth a summary of the change in the fair value of the warrant liability that is measured at fair value on a recurring basis. Schedule of change in the fair value of the warrant liability January 31, 2024 Balance on April 30, 2023 $ – Issuance of warrants 14,127,000 Change in fair value of warrant liability (2,633,000 ) Balance on January 31, 2024 $ 11,494,000 The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured on a recurring basis: January 31, 2024 Balance on April 30, 2023 $ – Issuance of convertible preferred stock with bifurcated embedded derivative liability 2,770,000 Change in fair value of bifurcated embedded derivative 663,000 Balance on January 31, 2024 $ 3,433,000 The fair values of financial instruments by class as of January 31, 2024 are as follows: Schedule of fair values of financial instruments Level 1 Level 2 Level 3 Financial Assets Convertible note receivable – investment in debt security $ – $ – $ 2,012,000 Warrant asset – – 2,710,000 Total $ – $ – $ 4,722,000 Assumptions used in the valuation of the Level 3 assets include time to expiration, discount rate, risk-free rate, volatility and probability of default.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended
	Jan. 31, 2024
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 15 – SUBSEQUENT EVENTS Stock Repurchase From February 1, 2024 to March 15, 2024, the Company repurchased 56,335 shares of common stock through the stock repurchase program for $119,73.

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended
	Jan. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation and Basis of Presentation	Principles of Consolidation and Basis of Presentation The Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries. The Company operates independently and through four wholly owned subsidiaries: (i) PharmaCyte Biotech Europe Limited; (ii) PharmaCyte Biotech Australia Pty. Ltd.; and (iii) Viridis Biotech, Inc. and are prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) and the Rules and Regulations of the Commission. Upon consolidation, intercompany balances and transactions are eliminated. The Company’s 14.3 325 Investments
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in accordance with U.S. GAAP. U.S. GAAP requires the use of estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities known to exist as of the date the financial statements are published and the reported amounts of revenues and expenses during the reporting period. Uncertainties with respect to such estimates and assumptions are inherent in the preparation of the Company’s condensed consolidated financial statements; accordingly, it is possible that the actual results could differ from these estimates and assumptions, which could have a material effect on the reported amounts of the Company’s condensed consolidated financial position and results of operations.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include cash in banks and short-term liquid investments purchased with maturities of three months or less.
Intangible Assets	Intangible Assets The Financial Accounting Standards Board (“FASB”) standard on goodwill and other intangible assets prescribes a two-step process for impairment testing of goodwill and indefinite-lived intangibles, which is performed annually, as well as when an event triggering impairment may have occurred. The first step tests for impairment, while the second step, if necessary, measures the impairment. The Company has elected to perform its annual analysis at the end of its reporting year. The Company’s intangible assets are in process R&D obtained through the acquisition of licensing agreements related to the Cell-in-a-Box ® 1,549,427 2,000,000 3,549,427 These intangible assets have an indefinite life; therefore, they are not amortizable. The Company concluded that there was no
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying value of an asset may not be fully recoverable. If the estimated future cash flows (undiscounted and without interest charges) from the use of an asset are less than carrying value, a write-down would be recorded to reduce the related asset to its estimated fair value. No
Convertible Note Receivable	Convertible Note Receivable As permitted under Financial Accounting Standards Board ("FASB”) ASC 825, Financial Instruments ("ASC 825”), the Company elects to account for its convertible note receivable, which meets the required criteria, at fair value at inception and at each subsequent reporting date. Subsequent changes in fair value, including interest, are recorded as a component of non-operating income (loss) in the condensed consolidated statements of operations. As a result of electing the fair value option, direct costs and fees related to the convertible note receivable were expensed as incurred. The Company estimates the fair value of the convertible note receivable using the income approach, which uses as inputs the fair value of debtor’s common stock and estimates for the equity volatility and volume volatility of debtor’s common stock, the time to expiration of the convertible note, the discount rate, the stated interest rate compared to the current market rate, the risk-free interest rate for a period that approximates the time to expiration, and probability of default. Therefore, the estimate of expected future volatility is based on the actual volatility of debtor’s common stock and historical volatility of debtor’s common stock utilizing a lookback period consistent with the time to expiration. The time to expiration is based on the contractual maturity date. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of measurement for time periods approximately equal to the time to expiration. Probability of default is estimated using the S&P Global default rate for companies with a similar credit rating to debtor’s.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Accounting Standards Codification (“ASC”) Topic 820, “Fair Value Measurements and Disclosures,” requires disclosure of the fair value of financial instruments held by the Company. ASC Topic 825, “Financial Instruments,” defines fair value, and establishes a three-level valuation hierarchy for disclosures of fair value measurement that enhances disclosure requirements for fair value measures. The carrying amounts reported in the Condensed Consolidated Balance Sheets for current assets and liabilities qualify as financial instruments and are a reasonable estimate of their fair values because of the short period between the origination of such instruments and their expected realization and their current market rate of interest. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of valuation hierarchy are defined as follows: · Level 1. Observable inputs such as quoted prices in active markets · Level 2. Inputs, other than the quoted prices in active markets, which are observable either directly or indirectly; and · Level 3. Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. These unobservable inputs are significant to the fair value measurement.
Income Taxes	Income Taxes Deferred taxes are calculated using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss and tax credit carry forwards, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. A valuation allowance is provided for deferred income tax assets when, in management’s judgment, based upon currently available information and other factors, it is more likely than not that all or a portion of such deferred income tax assets will not be realized. The determination of the need for a valuation allowance is based on an on-going evaluation of current information including, among other things, historical operating results, estimates of future earnings in different taxing jurisdictions and the expected timing of the reversals of temporary differences. The Company believes the determination to record a valuation allowance to reduce a deferred income tax asset is a significant accounting estimate because it is based on, among other things, an estimate of future taxable income in the U.S. and certain other jurisdictions, which is susceptible to change and may or may not occur, and because the impact of adjusting a valuation allowance may be material. In determining when to release the valuation allowance established against the Company’s net deferred income tax assets, the Company considers all available evidence, both positive and negative. Consistent with the Company’s policy, and because of the Company’s history of operating losses, the Company does not currently recognize the benefit of all its deferred tax assets, including tax loss carry forwards, which may be used to offset future taxable income. The Company continually assesses its ability to generate sufficient taxable income during future periods in which deferred tax assets may be realized. When the Company believes it is more likely than not that it will recover its deferred tax assets, the Company will reverse the valuation allowance as an income tax benefit in the condensed consolidated statements of operations. The U.S. GAAP method of accounting for uncertain tax positions utilizes a two-step approach to evaluate tax positions. Step one, recognition, requires evaluation of the tax position to determine if based solely on technical merits it is more likely than not to be sustained upon examination. Step two, measurement, is addressed only if a position is more likely than not to be sustained. In step two, the tax benefit is measured as the largest amount of benefit, determined on a cumulative probability basis, which is more likely than not to be realized upon ultimate settlement with tax authorities. If a position does not meet the more likely than not threshold for recognition in step one, no benefit is recorded until the first subsequent period in which the more likely than not standard is met, the issue is resolved with the taxing authorities or the statute of limitations expires. Positions previously recognized are derecognized when the Company subsequently determines the position no longer is more likely than not to be sustained. Evaluation of tax positions, their technical merits and measurements using cumulative probability are highly subjective management estimates. Actual results could differ materially from these estimates.
Consideration of Inflation Reduction Act Excise Tax	Consideration of Inflation Reduction Act Excise Tax On August 16, 2022, the Inflation Reduction Act of 2022 (the “IR Act”) was signed into federal law. The IR Act provides for, among other things, a new U.S. federal 1% excise tax on certain repurchases of stock by publicly-traded U.S. domestic corporations and certain U.S. domestic subsidiaries of publicly traded foreign corporations occurring on or after January 1, 2023. The excise tax is imposed on the repurchasing corporation itself, not its stockholders from which shares are repurchased. The amount of the excise tax is generally 1% of the fair market value of the shares repurchased at the time of the repurchase. However, for purposes of calculating the excise tax, repurchasing corporations are permitted to net the fair market value of certain new stock issuances against the fair market value of stock repurchases during the same taxable year. In addition, certain exceptions apply to the excise tax. The U.S. Department of the Treasury (the “Treasury”) has been given authority to provide regulations and other guidance to carry out and prevent the abuse or avoidance of the excise tax. The Company repurchased 8,342,821 27,293,217 178,833 404,717 270,230
Research and Development	Research and Development Research and development (“R&D”) expenses consist of costs incurred for direct and overhead-related research expenses and are expensed as incurred. Costs to acquire technologies, including licenses, which are utilized in research and development and that have no alternative future use are expensed when incurred. Technology developed for use in the Company’s product candidates is expensed as incurred until technological feasibility has been established. R&D costs for the three months ended January 31, 2024 and 2023 were $ 126,732 45,393 313,248 382,662
Stock-Based Compensation	Stock-Based Compensation The Company recognizes stock-based compensation expense for only those awards ultimately expected to vest on a straight-line basis over the requisite service period of the award. The Company estimates the fair value of stock options using a Black-Scholes-Merton valuation model. This model requires the input of highly subjective assumptions, including the option’s expected term and stock price volatility. In addition, judgment is also required in estimating the number of stock-based awards that are expected to be forfeited. Forfeitures are estimated based on historical experience at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The assumptions used in calculating the fair value of share-based payment awards represent management’s best estimates, but these estimates involve inherent uncertainties and the application of management’s judgment. Thus, if factors change and the Company uses different assumptions, the stock-based compensation expense could be materially different in the future.
Concentration of Credit Risk	Concentration of Credit Risk The Company has no significant off-balance-sheet concentrations of credit risk such as foreign exchange contracts, options contracts or other foreign hedging arrangements. The Company maintains most of its cash balance at financial institutions located throughout the United States. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation up to $ 250,000 16,480,000 1,100,000
Foreign Currency Translation	Foreign Currency Translation The Company translates the financial statements of its foreign subsidiaries from the local (functional) currencies to U.S. dollars in accordance with FASB ASC 830, Foreign Currency Matters

INVESTMENT IN DEBT AND EQUITY_2

INVESTMENT IN DEBT AND EQUITY SECURITIES (Tables)	9 Months Ended
	Jan. 31, 2024
Investments, Debt and Equity Securities [Abstract]
Schedule of notes and warrants receivable	Schedule of notes and warrants receivable Balance of Notes as of May 1, 2023 $ – Issued 1,874,000 Change in fair value 138,000 Balance of Notes as of January 31, 2024 $ 2,012,000 Balance of Warrants as of May 1, 2023 $ – Issued 3,126,000 Change in fair value (416,000 ) Balance of Warrants as of January 31, 2024 $ 2,710,000

ACCRUED EXPENSES (Tables)

ACCRUED EXPENSES (Tables)	9 Months Ended
	Jan. 31, 2024
Payables and Accruals [Abstract]
Schedule of accrued expenses	Schedule of accrued expenses January 31, 2024 April 30, 2023 Payroll related costs $ 158,803 $ 112,894 R&D costs, including related parties 287,310 287,310 Other, including excise tax on stock repurchases 328,326 58,096 Total $ 774,439 $ 458,300

STOCK OPTIONS AND WARRANTS (Tab

STOCK OPTIONS AND WARRANTS (Tables)	9 Months Ended
	Jan. 31, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of assumptions for options	Schedule of assumptions for options Nine Months Ended January 31, 2024 2023 Risk-free interest rate 4.42 3.30 Expected volatility 115 133 Expected lives (years) 5.1 3.5 Expected dividend yield 0.00 0.00
Schedule of stock option activity	Schedule of stock option activity Options Number of Options Weighted Average Grant Date Fair Value per Share Outstanding, April 30, 2023 281,269 $ 6.94 Issued 499,992 2.18 Expired (1,467 ) 89.10 Outstanding, January 31, 2024 779,794 $ 3.73 Exercisable, January 31, 2024 652,294 $ 4.04 Vested and expected to vest 779,794 $ 3.73
Schedule of options by exercise price	Schedule of options by exercise price Exercise Price Number of Weighted Weighted Number of Weighted Average $ 74.25 6,000 0.13 $ 74.25 6,000 $ 74.25 $ 57.00 800 0.64 $ 57.00 800 $ 57.00 $ 60.60 667 0.25 $ 60.60 667 $ 60.60 $ 55.50 333 0.41 $ 55.50 333 $ 55.50 $ 51.00 333 0.69 $ 51.00 333 $ 51.00 $ 61.20 6,000 0.92 $ 61.20 6,000 $ 61.20 $ 36.00 667 1.25 $ 36.00 667 $ 36.00 $ 37.05 333 1.41 $ 37.05 333 $ 37.05 $ 15.75 333 1.69 $ 15.75 333 $ 15.75 $ 10.05 6,000 1.92 $ 10.05 6,000 $ 10.05 $ 26.55 667 2.25 $ 26.55 667 $ 26.55 $ 16.20 333 2.41 $ 16.20 333 $ 16.20 $ 3.19 334 2.69 $ 3.19 334 $ 3.19 $ 2.50 6,000 2.92 $ 2.50 6,000 $ 2.50 $ 2.29 668 3.25 $ 2.29 668 $ 2.29 $ 2.24 334 3.41 $ 2.24 334 $ 2.24 $ 2.97 250,000 8.79 $ 2.97 250,000 $ 2.97 $ 2.18 499,992 9.81 $ 2.18 372,492 $ 2.18 Total 779,794 3.73 $ 4.04 652,294 $ 4.04
Schedule of warrant activity	Schedule of warrant activity Warrants Weighted Per Share Outstanding, April 30, 2023 9,890,847 $ 4.99 Issued 8,750,000 4.00 Exercised (70,000 ) – Expired – – Outstanding, January 31, 2024 18,570,847 – Exercisable, January 31, 2024 18,570,847 $ 4.54
Schedule of warrants outstanding and exercisable	Schedule of warrants outstanding and exercisable Exercise Prices Number of Weighted Weighted $ 4.25 1,506,141 2.53 $ 5.3125 264,706 2.52 $ 5.00 7,000,000 2.56 $ 6.25 1,050,000 2.55 $ 4.00 8,750,000 4.28 18,570,847 3.37 $ 4.54

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)	9 Months Ended
	Jan. 31, 2024
Earnings Per Share [Abstract]
Schedule of earnings (loss) per share	Schedule of earnings (loss) per share Three Months Ended January 31, 2024 2023 Net loss attributable to common stockholders $ (5,620,113 ) $ (764,136 ) Basic and diluted weighted average number of shares outstanding 8,606,957 18,995,442 Basic and diluted loss per share $ (0.65 ) $ (0.04 ) Nine Months Ended January 31, 2024 2023 Net loss attributable to common stockholders $ (14,696,861 ) $ (4,189,655 ) Basic and diluted weighted average number of shares outstanding 9,991,326 20,051,617 Basic and diluted loss per share $ (1.47 ) $ (0.21 )
Schedule of potentially dilutive securities	Schedule of potentially dilutive securities Nine Months Ended January 31, 2024 2023 Excluded options 779,794 281,936 Excluded warrants 18,570,847 9,890,847 Series B convertible preferred stock 5,929,053 – Total preferred stock, options and warrants 25,279,694 10,172,783

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended
	Jan. 31, 2024
Fair Value Disclosures [Abstract]
Schedule of liabilities measured at fair value on a recurring basis	Schedule of liabilities measured at fair value on a recurring basis Description Level January 31, 2024 April 30, 2023 Liabilities: Warrant liability (Note 5) 3 $ 11,494,000 $ – Bifurcated embedded derivative (Note 11) 3 $ 3,433,000 $ –
Schedule of change in the fair value of the warrant liability	Schedule of change in the fair value of the warrant liability January 31, 2024 Balance on April 30, 2023 $ – Issuance of warrants 14,127,000 Change in fair value of warrant liability (2,633,000 ) Balance on January 31, 2024 $ 11,494,000 The following table sets forth a summary of the change in the fair value of the bifurcated embedded derivative liability that is measured on a recurring basis: January 31, 2024 Balance on April 30, 2023 $ – Issuance of convertible preferred stock with bifurcated embedded derivative liability 2,770,000 Change in fair value of bifurcated embedded derivative 663,000 Balance on January 31, 2024 $ 3,433,000
Schedule of fair values of financial instruments	Schedule of fair values of financial instruments Level 1 Level 2 Level 3 Financial Assets Convertible note receivable – investment in debt security $ – $ – $ 2,012,000 Warrant asset – – 2,710,000 Total $ – $ – $ 4,722,000

NATURE OF BUSINESS (Details Nar

NATURE OF BUSINESS (Details Narrative) - shares	Jan. 31, 2024	Sep. 06, 2023	Apr. 30, 2023
Common stock authorized shares	200,000,000		200,000,000
Preferred stock authorized shares	10,000,000		10,000,000
Common Stock [Member]
Common stock authorized shares		200,000,000
Preferred Stock [Member]
Preferred stock authorized shares		10,000,000

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	May 11, 2023	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Intangible assets		$ 3,549,427		$ 3,549,427
Impairment on intangible assets				0	$ 0
Impairment charges				$ 0	0
Number of shares repurchased	8,085,879	178,833		256,942
Payments for repurchase of common stock		$ 404,717		$ 27,022,987	9,254,005
Accrued excise tax		270,230		270,230
Research and development expenses		126,732	$ 45,393	313,248	382,662
Federal deposit insurance amount		250,000		250,000
Cash uninsured amount		16,480,000	$ 1,100,000	$ 16,480,000	$ 1,100,000
Common Stock [Member]
Number of shares repurchased				8,342,821
Payments for repurchase of common stock				$ 27,293,217
Cell In A Box [Member]
Intangible assets		1,549,427		1,549,427
Diabetes License [Member]
Intangible assets		$ 2,000,000		$ 2,000,000
S G Austria [Member]
Equity percentage		14.30%		14.30%

INVESTMENT IN DEBT AND EQUITY_3

INVESTMENT IN DEBT AND EQUITY SECURITIES (Details - Note and Warrants) - USD ($)	3 Months Ended		8 Months Ended	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2024	Jan. 31, 2023
Investments, Debt and Equity Securities [Abstract]
Beginning balance of notes			$ 0	$ 0
Issued note			1,874,000
Change in fair value	$ 138,000	$ 0	138,000	138,000	$ 0
Ending balance of notes	2,012,000		2,012,000	2,012,000
Beginning balance of warrants asset			0	0
Issued warrants			3,126,000
Change in fair value			(416,000)
Ending balance of warrants asset	$ 2,710,000		$ 2,710,000	$ 2,710,000

INVESTMENT IN DEBT AND EQUITY_4

INVESTMENT IN DEBT AND EQUITY SECURITIES (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	Nov. 14, 2023	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Securities Financing Transaction [Line Items]
Gain (loss) on investment		$ (416,000)	$ 0	$ (416,000)	$ 0
Gain (Loss) on Investments		416,000	$ 0	416,000	$ 0
Femasys Note [Member]
Securities Financing Transaction [Line Items]
Investment fair value	$ 1,874,000
Gain (loss) on investment		138,000		138,000
Gain (Loss) on Investments		(138,000)		(138,000)
Femasys Warrants [Member]
Securities Financing Transaction [Line Items]
Investment fair value	3,126,000
Gain (loss) on investment		(416,000)		(416,000)
Gain (Loss) on Investments		$ 416,000		$ 416,000
Femasys Purchase Agreement [Member]
Securities Financing Transaction [Line Items]
Receivable face amount	$ 5,000,000
Receivable conversion price	$ 1.18
Investment description	The Femasys Notes accrue interest at 6.0% per annum, payable annually, and mature two years after the date of issuance.
Femasys Warrant description	The Femasys Warrants expire five years from the date of issuance.
Femasys Purchase Agreement [Member] | Femasys Series A Warrants [Member]
Securities Financing Transaction [Line Items]
Warrant assets, shares	4,237,288
Warrant exercise price	$ 1.18
Femasys Purchase Agreement [Member] | Femasys Shares [Member]
Securities Financing Transaction [Line Items]
Receivable conversion price	$ 1.475
Investment shares	4,237,288

ACCRUED EXPENSES (Details)

ACCRUED EXPENSES (Details) - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Payables and Accruals [Abstract]
Payroll related costs	$ 158,803	$ 112,894
R&D costs, including related parties	287,310	287,310
Other, including excise tax on stock repurchases	328,326	58,096
Total	$ 774,439	$ 458,300

COMMON STOCK TRANSACTIONS (Deta

COMMON STOCK TRANSACTIONS (Details Narrative) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
	Jan. 31, 2022	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023	Apr. 30, 2023
Class of Stock [Line Items]
Number of shares vested				0
Number of shares granted				0
Number of shares expired				0
Executive Officers [Member] | Common Stock [Member] | Compensation Agreement 2022 [Member]
Class of Stock [Line Items]
Share based compensation gross	4,400
Share based compensation expenses				$ 0	$ 7,333
Number of non vested shares		0		0		0
Three Nonemployee [Member] | Common Stock [Member] | Director Letter Agreement [Member]
Class of Stock [Line Items]
Share based compensation gross					1,002
Share based compensation expenses		$ 0	$ 0	$ 0	$ 2,278
Number of non vested shares		0	0	0	0

STOCK OPTIONS AND WARRANTS (Det

STOCK OPTIONS AND WARRANTS (Details - Option Assumptions) - Employee Options [Member]	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk-free interest rate	4.42%	3.30%
Expected volatility	115%	133%
Expected lives (years)	5 years 1 month 6 days	3 years 6 months
Expected dividend yield	0%	0%

STOCK OPTIONS AND WARRANTS (D_2

STOCK OPTIONS AND WARRANTS (Details - Option activity) - Equity Option [Member]	9 Months Ended
	Jan. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of options outstanding, beginning | shares	281,269
Weighted average grant date fair value, beginning | $ / shares	$ 6.94
Number of options, issued | shares	499,992
Weighted average grant date fair value, issued | $ / shares	$ 2.18
Number of options, expired | shares	(1,467)
Weighted average grant date fair value, expired | $ / shares	$ 89.10
Number of options outstanding, ending | shares	779,794
Weighted average grant date fair value, ending | $ / shares	$ 3.73
Number of options exercisable | shares	652,294
Weighted average grant date fair value, exercisable | $ / shares	$ 4.04
Number of options vested and expected to vest | shares	779,794
Weighted average grant date fair value, vested and expected to vest | $ / shares	$ 3.73

STOCK OPTIONS AND WARRANTS (D_3

STOCK OPTIONS AND WARRANTS (Details - Options by exercise price) - $ / shares	9 Months Ended
	Jan. 31, 2024	Apr. 30, 2023
Equity Option [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	779,794	281,269
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	3 years 8 months 23 days
Weighted Average Exercisable Price Per Share	$ 4.04
Number of Options Exercisable	652,294
Weighted Average Exercise Price of Exercisable Options	$ 4.04
Exercise Price 74.25 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	6,000
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	1 month 17 days
Weighted Average Exercisable Price Per Share	$ 74.25
Number of Options Exercisable	6,000
Weighted Average Exercise Price of Exercisable Options	$ 74.25
Exercise Price 57.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	800
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	7 months 20 days
Weighted Average Exercisable Price Per Share	$ 57
Number of Options Exercisable	800
Weighted Average Exercise Price of Exercisable Options	$ 57
Exercise Price 60.60 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	667
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	3 months
Weighted Average Exercisable Price Per Share	$ 60.60
Number of Options Exercisable	667
Weighted Average Exercise Price of Exercisable Options	$ 60.60
Exercise Price 55.50 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	333
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	4 months 28 days
Weighted Average Exercisable Price Per Share	$ 55.50
Number of Options Exercisable	333
Weighted Average Exercise Price of Exercisable Options	$ 55.50
Exercise Price 51.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	333
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	8 months 8 days
Weighted Average Exercisable Price Per Share	$ 51
Number of Options Exercisable	333
Weighted Average Exercise Price of Exercisable Options	$ 51
Exercise Price 61.20 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	6,000
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	11 months 1 day
Weighted Average Exercisable Price Per Share	$ 61.20
Number of Options Exercisable	6,000
Weighted Average Exercise Price of Exercisable Options	$ 61.20
Exercise Price 36.00 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	667
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	1 year 3 months
Weighted Average Exercisable Price Per Share	$ 36
Number of Options Exercisable	667
Weighted Average Exercise Price of Exercisable Options	$ 36
Exercise Price 37.05 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	333
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	1 year 4 months 28 days
Weighted Average Exercisable Price Per Share	$ 37.05
Number of Options Exercisable	333
Weighted Average Exercise Price of Exercisable Options	$ 37.05
Exercise Price 15.75 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	333
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	1 year 8 months 8 days
Weighted Average Exercisable Price Per Share	$ 15.75
Number of Options Exercisable	333
Weighted Average Exercise Price of Exercisable Options	$ 15.75
Exercise Price 10.05 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	6,000
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	1 year 11 months 1 day
Weighted Average Exercisable Price Per Share	$ 10.05
Number of Options Exercisable	6,000
Weighted Average Exercise Price of Exercisable Options	$ 10.05
Exercise Price 26.55 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	667
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	2 years 3 months
Weighted Average Exercisable Price Per Share	$ 26.55
Number of Options Exercisable	667
Weighted Average Exercise Price of Exercisable Options	$ 26.55
Exercise Price 16.20 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	333
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	2 years 4 months 28 days
Weighted Average Exercisable Price Per Share	$ 16.20
Number of Options Exercisable	333
Weighted Average Exercise Price of Exercisable Options	$ 16.20
Exercise Price 3.19 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	334
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	2 years 8 months 8 days
Weighted Average Exercisable Price Per Share	$ 3.19
Number of Options Exercisable	334
Weighted Average Exercise Price of Exercisable Options	$ 3.19
Exercise Price 2.50 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	6,000
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	2 years 11 months 1 day
Weighted Average Exercisable Price Per Share	$ 2.50
Number of Options Exercisable	6,000
Weighted Average Exercise Price of Exercisable Options	$ 2.50
Exercise Price 2.29 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	668
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	3 years 3 months
Weighted Average Exercisable Price Per Share	$ 2.29
Number of Options Exercisable	668
Weighted Average Exercise Price of Exercisable Options	$ 2.29
Exercise Price 2.24 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	334
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	3 years 4 months 28 days
Weighted Average Exercisable Price Per Share	$ 2.24
Number of Options Exercisable	334
Weighted Average Exercise Price of Exercisable Options	$ 2.24
Exercise Price 2.97 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	250,000
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	8 years 9 months 14 days
Weighted Average Exercisable Price Per Share	$ 2.97
Number of Options Exercisable	250,000
Weighted Average Exercise Price of Exercisable Options	$ 2.97
Exercise Price 2.18 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	499,992
Weighted Average Remaining Contractual Life (Years) of Outstanding Options	9 years 9 months 21 days
Weighted Average Exercisable Price Per Share	$ 2.18
Number of Options Exercisable	372,492
Weighted Average Exercise Price of Exercisable Options	$ 2.18

STOCK OPTIONS AND WARRANTS (D_4

STOCK OPTIONS AND WARRANTS (Details - Warrant activity) - Warrant [Member]	9 Months Ended
	Jan. 31, 2024 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants outstanding, beginning balance | shares	9,890,847
Weighted average exercise price warrants outstanding, beginning balance | $ / shares	$ 4.99
Warrants issued | shares	8,750,000
Weighted average exercise price warrants issued | $ / shares	$ 4
Warrants exercised | shares	(70,000)
Weighted average exercise price warrants Exercised | $ / shares	$ 0
Warrants expired | shares	0
Weighted average exercise price warrants Expired | $ / shares	$ 0
Warrants outstanding, ending balance | shares	18,570,847
Weighted average exercise price warrants outstanding, ending balance | $ / shares	$ 0
Warrants exercisable | shares	18,570,847
Weighted average exercise price warrants exercisable | $ / shares	$ 4.54

STOCK OPTIONS AND WARRANTS (D_5

STOCK OPTIONS AND WARRANTS (Details - Warrants by exercise price) - Warrant [Member] - $ / shares	9 Months Ended
	Jan. 31, 2024	Apr. 30, 2023
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 0	$ 4.99
Number of warrants exercisable	18,570,847
Weighted average remaining contractual life (years)	3 years 4 months 13 days
Weighted average exercise price exercisable	$ 4.54
Warrant 1 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 4.25
Number of warrants exercisable	1,506,141
Weighted average remaining contractual life (years)	2 years 6 months 10 days
Warrant 2 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 5.3125
Number of warrants exercisable	264,706
Weighted average remaining contractual life (years)	2 years 6 months 7 days
Warrant 3 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 5
Number of warrants exercisable	7,000,000
Weighted average remaining contractual life (years)	2 years 6 months 21 days
Warrant 4 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 6.25
Number of warrants exercisable	1,050,000
Weighted average remaining contractual life (years)	2 years 6 months 18 days
Warrant 5 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Warrants exercise prices	$ 4
Number of warrants exercisable	8,750,000
Weighted average remaining contractual life (years)	4 years 3 months 10 days

STOCK OPTIONS AND WARRANTS (D_6

STOCK OPTIONS AND WARRANTS (Details Narrative) - USD ($)		3 Months Ended		9 Months Ended
	May 10, 2023	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023	Apr. 30, 2023	Dec. 28, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Unvested stock options				127,500
Stock-based compensation				$ 0	$ 7,334
Change in fair value of warrant liability		$ 10,000	$ 0	$ 2,633,000	$ 0
Private Placement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase of common stock shares	8,750,000
Purchase of common stock price per share	$ 4
Fair value of warrants issued	$ 14,127,000
Transaction costs for issuance of warrants	$ 900,000
Equity Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock options outstanding		779,794		779,794		281,269
Number of shares granted				499,992
Aggregate intrinsic value		$ 3,725		$ 3,725
Equity Option [Member] | Employees [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares granted				499,992	251,002
Stock-based compensation		674,693	$ 629,264	$ 674,693	$ 638,072
Employee service unrecognized compensation expense		$ 234,692		$ 234,692
Warrant [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Purchase of common stock price per share		$ 0		$ 0		$ 4.99
Fair value of the warrants				$ 11,494,000
Equity Plan 2022 [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares available							2,750,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
S G Austria [Member]
Related Party Transaction [Line Items]
Purchases from related parties	$ 0	$ 0	$ 0	$ 64,000
Vin De Bona [Member]
Related Party Transaction [Line Items]
Consulting fees	$ 2,600	$ 2,400	$ 5,300	$ 47,500
S G Australia [Member]
Related Party Transaction [Line Items]
Equity interest owned	14.30%		14.30%

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Rent and lease expense	$ 6,825	$ 5,789	$ 22,424	$ 17,041

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	Jan. 31, 2024	Jan. 31, 2023
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 58,018,000
Deferred Tax Assets, Operating Loss Carryforwards, Domestic	49,924,000
Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration	39,336,000
Accrued interest	0	$ 0
Federal [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	20,958,000
State [Member]
Operating Loss Carryforwards [Line Items]
Operating Loss Carryforwards	$ 9,117,000

EARNINGS PER SHARE (Details - P

EARNINGS PER SHARE (Details - Per Share Calculation) - USD ($)	3 Months Ended		9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023	Jan. 31, 2024	Jan. 31, 2023
Earnings Per Share [Abstract]
Net loss attributable to common stockholders	$ (5,620,113)	$ (764,136)	$ (14,696,861)	$ (4,189,655)
Basic weighted average number of shares outstanding	8,606,957	18,995,442	9,991,326	20,051,617
Diluted weighted average number of shares outstanding	8,606,957	18,995,442	9,991,326	20,051,617
Basic loss per share	$ (0.65)	$ (0.04)	$ (1.47)	$ (0.21)
Diluted loss per share	$ (0.65)	$ (0.04)	$ (1.47)	$ (0.21)

EARNINGS PER SHARE (Details -

EARNINGS PER SHARE (Details - Diluted Shares) - shares	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	25,279,694	10,172,783
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	779,794	281,936
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	18,570,847	9,890,847
Preferred Stock Including Additional Paid in Capital [Member] | Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares	5,929,053	0

PREFERRED STOCK (Details Narrat

PREFERRED STOCK (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Jan. 31, 2024	Jan. 31, 2024	Apr. 30, 2023	Jan. 31, 2023
Class of Stock [Line Items]
Preferred stock, shares authorized	10,000,000	10,000,000	10,000,000
Gain on derivative liability	$ 700,000	$ 700,000
Fair value of embedded derivative	3,400,000	3,400,000
Payments for repurchase of redeemable preferred stock		5,770,833
Payments for repurchase of redeemable preferred stock		491,616
Preferred Stock [Member]
Class of Stock [Line Items]
Discount on fair value	18,200,000	18,200,000
Preferred Stock [Member] | Fair Value Of Embedded Derivative [Member]
Class of Stock [Line Items]
Discount on fair value	2,800,000	2,800,000
Preferred Stock [Member] | Stock Issuance Costs [Member]
Class of Stock [Line Items]
Discount on fair value	1,300,000	1,300,000
Preferred Stock [Member] | Fair Value Of Warrants [Member]
Class of Stock [Line Items]
Discount on fair value	$ 14,100,000	$ 14,100,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, par value	$ 0.0001	$ 0.0001	$ 0.0001
Preferred stock shares designated	35,000	35,000
Temporary equity, shares issued	23,397	23,397	0	0
Temporary equity, shares outstanding	23,397	23,397	0
Shares excluded for redemption	8,083	8,083	0
Accretion expense	$ 8,041,520	$ 11,995,681
Deemed dividend		$ 499,417

TREASURY STOCK (Details Narrati

TREASURY STOCK (Details Narrative) - USD ($)		3 Months Ended						9 Months Ended
	May 11, 2023	Jan. 31, 2024	Oct. 31, 2023	Jul. 31, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Jan. 31, 2024	Apr. 30, 2023	May 31, 2022
Class of Stock [Line Items]
Aggregate purchase price	$ 26,721,897									$ 10,000,000
Number of shares repurchased	8,085,879	178,833						256,942
Number of shares repurchased, value		$ 404,717	$ 166,603	$ 26,721,897	$ 3,778,114	$ 3,385,044	$ 2,090,847
Stock repurchase program, remaining amount		$ 5,868,058						$ 5,868,058
Treasury stock, common shares		13,150,919						13,150,919	4,808,098
Treasury stock, value		$ 40,853,840						$ 40,853,840	$ 13,560,623
Treasury Stock, Common [Member]
Class of Stock [Line Items]
Number of shares repurchased								5,065,040
Number of shares repurchased, value								$ 14,131,942

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details - Fair value) - Fair Value, Recurring [Member] - USD ($)	Jan. 31, 2024	Apr. 30, 2023
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 11,494,000	$ 0
Bifurcated Embedded Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	3,433,000	0
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	11,494,000	0
Fair Value, Inputs, Level 3 [Member] | Bifurcated Embedded Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 3,433,000	$ 0

FAIR VALUE MEASUREMENTS (Deta_2

FAIR VALUE MEASUREMENTS (Details - Changes in Fair Value) - Fair Value, Recurring [Member]	9 Months Ended
	Jan. 31, 2024 USD ($)
Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the warrant liability at beginning	$ 0
Issuance of convertible preferred stock with bifurcated embedded derivative liability	14,127,000
Change in fair value of bifurcated embedded derivative	(2,633,000)
Fair value of the warrant liability at ending	11,494,000
Bifurcated Embedded Derivative [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of the warrant liability at beginning	0
Issuance of convertible preferred stock with bifurcated embedded derivative liability	2,770,000
Change in fair value of bifurcated embedded derivative	663,000
Fair value of the warrant liability at ending	$ 3,433,000

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details - Fair Values Of Financial Instruments)	Jan. 31, 2024 USD ($)
Fair Value, Inputs, Level 1 [Member]
Financial Assets
Total	$ 0
Fair Value, Inputs, Level 1 [Member] | Convertible Note Receivable [Member]
Financial Assets
Total	0
Fair Value, Inputs, Level 1 [Member] | Warrant Asset [Member]
Financial Assets
Total	0
Fair Value, Inputs, Level 2 [Member]
Financial Assets
Total	0
Fair Value, Inputs, Level 2 [Member] | Convertible Note Receivable [Member]
Financial Assets
Total	0
Fair Value, Inputs, Level 2 [Member] | Warrant Asset [Member]
Financial Assets
Total	0
Fair Value, Inputs, Level 3 [Member]
Financial Assets
Total	4,722,000
Fair Value, Inputs, Level 3 [Member] | Convertible Note Receivable [Member]
Financial Assets
Total	2,012,000
Fair Value, Inputs, Level 3 [Member] | Warrant Asset [Member]
Financial Assets
Total	$ 2,710,000